Lysoway Therapeutics

Executive Summary

Lysoway Therapeutics is a preclinical-stage biotechnology company pioneering small-molecule modulators of lysosomal ion channels, including TRPML1 and TMEM175, to restore autophagy-lysosomal function in age-related neurodegenerative diseases (Alzheimer's, Parkinson's) and rare lysosomal storage disorders. Founded in 2021 and headquartered in Cambridge, MA, the company is privately held with no disclosed funding rounds. Its brain-penetrant drug candidates target genetically validated mechanisms, such as TMEM175 mutations linked to Parkinson's disease. While still in early research, Lysoway's novel approach addresses high unmet medical needs. Near-term catalysts include the initiation of IND-enabling studies, release of key preclinical efficacy data, and potential strategic partnerships or Series A financing. The company's scientific rationale is compelling, but significant risks remain due to the early stage and lack of clinical validation.

Upcoming Catalysts (preview)

• 2027Initiation of Phase 1 clinical trial for TRPML1 agonist lead program25% success
• 2026Presentation of preclinical in vivo efficacy data at major conference (e.g., AD/PD or SfN)60% success
• 2026Announcement of Series A financing or partnership with a larger pharma50% success